Cognitive ⏱ Half-life: Not fully characterized. Oral bioavailability confirmed in animal models. Experimental

Dihexa

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide)

Buy Now

Evidence at a Glance

Regulatory statusExperimental
Angiotensin-IV analog never tested in humans; foundational HGF/c-Met mechanism paper (Benoist 2014) retracted April 2025 for fabricated data.
Human evidenceNone
Animal evidenceLimited

Dihexa is an experimental cognition compound supported only by rodent data, and its foundational mechanism paper was retracted in 2025 amid findings of fabricated data.

What the research does not support

  • It has never been tested in a human clinical trial and is not proven to improve memory or treat Alzheimer's disease.
  • The claim that it is 'seven orders of magnitude more potent than BDNF' traces to a 2014 paper retracted in April 2025 for falsified data.
  • It is not an approved drug; the related clinical candidate fosgonimeton failed its Alzheimer's trial (LIFT-AD) in 2024.
  • Its long-term safety, including any cancer risk from HGF/c-Met pathway activation, is unknown in humans.
Half-Life
Not fully characterized. Oral bioavailability confirmed in animal models.
Mol. Weight
507.63 g/mol

What is Dihexa?

Dihexa is one of the most potent synaptogenic compounds ever identified in research — an orally bioavailable peptidomimetic that promotes new synapse formation through the HGF/c-Met pathway at concentrations millions of times lower than traditional neurotrophic factors.

Research Applications

Synaptogenesis research, cognitive restoration models, HGF/c-Met signaling, Alzheimer’s disease models, and neurotrophic factor pharmacology.

Dosage Information (Research Use)

Animal research: 0.25-2 mg/kg oral or IP. Human dosing not established. Extreme potency requires careful protocol design. Research use only.

Reconstitution & Handling

Orally bioavailable — typically supplied as capsules or powder for oral administration. Can also be dissolved in DMSO for research injection protocols.

Half-Life & Pharmacokinetics

Not fully characterized. Oral bioavailability confirmed in animal models.

Reported Observations in Literature

No published toxicity data in animals at research doses. Theoretical concern about c-Met pathway activation and cell proliferation — not confirmed in published data. No human safety data exists.

Key Research References

  • McCoy AT, et al. “Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.” J Pharmacol Exp Ther. 2013

How Dihexa Works

Dihexa is a synthetic peptidomimetic derived from angiotensin IV that acts on hepatocyte growth factor (HGF) and its receptor c-Met. It facilitates HGF/c-Met dimerization, dramatically amplifying synaptogenic (new synapse formation) signaling. Published data describes it as approximately 10 million times more potent than BDNF at promoting new synapse connections. Orally bioavailable and blood-brain barrier permeable — unusual for a compound of this potency targeting CNS pathways.

Research Findings

Animal studies (rats with scopolamine-induced cognitive impairment) showed full restoration of cognitive function. The extreme potency of synaptogenic signaling has raised theoretical concerns about uncontrolled cell proliferation, though no tumorigenic effects have been published. Very early-stage research — no human clinical trials. The combination of oral bioavailability, BBB penetrance, and extreme potency makes it both promising and requiring careful research protocol design.

Dosage & Administration

Animal research: 0.25-2 mg/kg oral or IP. Human dosing not established. Extreme potency requires careful protocol design. Research use only.

Safety & Side Effects

No published toxicity data in animals at research doses. Theoretical concern about c-Met pathway activation and cell proliferation — not confirmed in published data. No human safety data exists.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence N-hexanoic-Tyr-Ile-(6) aminohexanoic amide (peptidomimetic)
Molecular Weight 507.63 g/mol
Half-Life Not fully characterized. Oral bioavailability confirmed in animal models.
Available Sizes 500mg (oral)
Storage Room temperature, protect from moisture and light.

Key Research References

  • McCoy AT, et al. "Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents." J Pharmacol Exp Ther. 2013

Get Dihexa from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Buy Now

Related Peptides

View all →
P21
Cognitive
CNTF-derived tetrapeptide researched for neurogenesis, cognitive enhancement, and neurodegenerative disease models.
Cognitive
Enhanced-stability version of Selank with improved bioavailability and prolonged anxiolytic/nootropic effects.
Cognitive
TREK-1 potassium channel blocker researched as a rapid-acting mood modulator with antidepressant-like effects in animal models.